Children's toxicology from bench to bed--Liver injury (1): Drug-induced metabolic disturbance--toxicity of 5-FU for pyrimidine metabolic disorders and pivalic acid for carnitine metabolism.
Congenital disorders of metabolism show a wide spectrum of symptoms as a consequence of impairment of a certain metabolic pathway by mutated enzymes resulting in abnormal accumulation of enzyme substrates, deficiency of expected products, and abnormal burden to collateral metabolic pathways, etc. However, in some occasions, depending on which pathway up to what degree of disturbance, it can be asymptomatic until a certain kind of burden is placed on to the patient. Enzyme deficiency involved in pyrimidine degradation, such as Dihydropyrimidine dehydrogenase (DPD) and Dihydropyrimidinase (DHP), has been reported with convulsion or autism as symptoms, but many asymptomatic cases are also reported. However, when the patients are treated with 5-fluorouracil, a pyrimidine analogue anticancer drug, lethal side-effects can be seen even in asymptomatic patients. Some oral cephem antibiotics have pivalic acid side chain to increase absorption rate at intestine. These antibiotics degrade into active antibiotics and pivalic acid at the intestinal wall. This pivalic acid is carnitine-conjugated and excreted into urine. Carnitine acts as a carrier of long chain fatty acid to mitochondria and to beta-oxidation, thus an important molecule for energy production by beta-oxidation and maintenance of mitochondrial function. Because of this, long term administration of such antibiotics could induce depletion of carnitine from the body and lead to low ketotic hypoglycemia, convulsion and consciousness disturbance. This paper reports some possible serious side effects closely linked to drug metabolism.
Ito
Tetsuya
T
Nagoya City University, Graduate School of Medical Sciences, Department of Neonatology and Pediatrics, Aichi, Japan. itotetsu@med.nagoya-cu.ac.jp
D000581:Amidohydrolases / Q000172:deficiency; D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000378:metabolism / Q000633:toxicity*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002331:Carnitine / Q000378:metabolism*; D002511:Cephalosporins / Q000009:adverse effects* / Q000378:metabolism / Q000633:toxicity*; D002648:Child; D054067:Dihydropyrimidine Dehydrogenase Deficiency / Q000378:metabolism; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects* / Q000378:metabolism / Q000633:toxicity*; D006801:Humans; D007408:Intestinal Absorption; D010421:Pentanoic Acids / Q000378:metabolism*; D011686:Purine-Pyrimidine Metabolism, Inborn Errors / Q000378:metabolism*; D011743:Pyrimidines / Q000378:metabolism*; D051381:Rats
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D002511:Cephalosporins; D010421:Pentanoic Acids; D011743:Pyrimidines; C005566:pivalic acid; D000581:Amidohydrolases; C020047:dihydropyrimidinase; C030986:pyrimidine; D002331:Carnitine; D005472:Fluorouracil